Cardinal Health's FY2026 EPS Beat Confirms Specialty Shift, But Valuation Remains Rich

What happened

Cardinal Health reported FY2026 non-GAAP EPS of $11.26, surpassing initial guidance and marking over 30% growth, while revenue slightly missed as the profit mix shifted toward higher-margin specialty and 'Other' businesses. Management guided FY2027 EPS growth of 13-15%, implying continued double-digit expansion on an elevated base, with the article's author estimating $13.10 and setting a $258-$275 target range. However, this strong performance is built on non-GAAP metrics that exclude significant acquisition-related amortization and compensation, and the company's GAAP earnings remain much lower, raising questions about earnings quality. The stock has already re-rated significantly, trading near $241 versus the master report's trim level of $235, with substantial risks from CVS concentration, IRA drug pricing, and integration of recent MSO acquisitions. While the specialty pivot is real, the market is now pricing in flawless execution, leaving minimal margin of safety if growth normalizes or policy pressures intensify.

Implication

The FY2026 results confirm the specialty/MSO strategy is delivering, with non-GAAP EPS growth exceeding expectations and management guiding for further double-digit growth in FY2027. However, the stock's valuation (around 20x forward non-GAAP EPS) leaves little room for error, and the persistent gap between GAAP and non-GAAP earnings signals that true economic profits are lower than headline numbers suggest. Key risks—CVS concentration (30% of revenue), IRA-related margin compression, and integration challenges from recent MSO acquisitions—could derail the trajectory if they materialize over the next 12-18 months. Given the master report's POTENTIAL SELL rating with trim above $235, investors should consider reducing positions into strength, particularly if the stock approaches the $258-$275 target range cited in the article. For those without a position, waiting for a pullback toward the $185-200 area would offer a better risk/reward, while monitoring GAAP earnings and free cash flow conversion for signs of durability.

Thesis delta

The FY2026 EPS beat and FY2027 guidance strengthen the specialty growth narrative, but they also push the stock further above our trim level, exacerbating valuation risk. We maintain our cautious stance, though the upside case now rests on continued flawless execution; any slip in growth or margin would justify a significant de-rating.